| Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia (NCT00435370) | Baylor College of Medicine | 2006-11-01 |
| Supervised Treatment of Schizophrenia, a Randomized Controlled Trial. (NCT00392249) | Lady Reading Hospital, Pakistan | 2006-11-01 |
| Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint (NCT00366704) | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-11-01 |
| Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine (NCT00401973) | Eli Lilly and Company | 2006-11-01 |
| Antipsychotic Polypharmacy in Schizophrenia (NCT00493233) | Centre for Addiction and Mental Health | 2006-11-01 |
| Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism- (NCT00392197) | Otsuka Pharmaceutical Co., Ltd. | 2006-11-01 |
| Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia (NCT00404573) | Forest Laboratories | 2006-11-01 |
| Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers (NCT00448890) | GlaxoSmithKline | 2006-11-01 |
| Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812 (NCT00411866) | GlaxoSmithKline | 2006-10-13 |
| L-Theanine in the Management of Schizophrenia (NCT00372151) | Sha'ar Menashe Mental Health Center | 2006-10-01 |
| ECT Schizophrenia Serotonin Study (NCT00278668) | Sha'ar Menashe Mental Health Center | 2006-10-01 |
| Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia (NCT00463372) | Pfizer | 2006-10-01 |
| Effect of Single Dose Intranasal Insulin On Cognitive Function (NCT00646581) | University of Massachusetts, Worcester | 2006-10-01 |
| Exploratory Cognition Study of Sertindole in Patients With Schizophrenia (NCT00759421) | H. Lundbeck A/S | 2006-10-01 |
| Measuring Smoking Behavior in People With Schizophrenia and Bipolar Disorder (NCT00382915) | University of Medicine and Dentistry of New Jersey | 2006-10-01 |
| Anatomical and Structural Connectivity in Two Psychotic Phenotypes : Periodic Catatonia and Cataphasia (NCT02868879) | University Hospital, Strasbourg, France | 2006-09-25 |
| Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia (NCT00833547) | Massachusetts General Hospital | 2006-09-01 |
| A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder (NCT00892125) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-09-01 |
| Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia (NCT00742079) | Massachusetts General Hospital | 2006-09-01 |
| Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics (NCT00290121) | Université de Montréal | 2006-09-01 |
| Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism (NCT00463346) | Yale University | 2006-09-01 |
| How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs (NCT00514423) | Technical University of Munich | 2006-09-01 |
| Augmenting Clozapine With Sertindole - SERCLOZ (NCT00345982) | University of Aarhus | 2006-09-01 |
| Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness (NCT02334228) | Dartmouth-Hitchcock Medical Center | 2006-09-01 |
| Attention and Visual Perception in Schizophrenia: A Functional Magnetic Resonance Imaging (fMRI) Study (NCT00350935) | University Hospital, Strasbourg, France | 2006-09-01 |
| Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia (NCT00395915) | Universita di Verona | 2006-09-01 |
| Brain Activation Patterns in Schizophrenia After Computerized Cognitive Skills Training (NCT00431223) | Manhattan Psychiatric Center | 2006-09-01 |
| Long-Acting Injectable Risperidone in the Treatment of Schizophrenia (NCT00132314) | US Department of Veterans Affairs | 2006-09-01 |
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness (NCT00661869) | Manhattan Psychiatric Center | 2006-09-01 |
| Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia (NCT00358852) | Janssen-Cilag, S.A. | 2006-08-01 |
| Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia (NCT00361543) | The Alfred | 2006-08-01 |
| Health Evaluation of Abilify Long-term Therapy (NCT00520650) | Taiwan Otsuka Pharm. Co., Ltd | 2006-08-01 |
| The New Strategy for Pharmacological Treatment in People With Schizophrenia (NCT00352339) | Inje University | 2006-08-01 |
| Staccato Loxapine in Agitation (Proof of Concept) (NCT00369577) | Alexza Pharmaceuticals, Inc. | 2006-08-01 |
| Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder (NCT00373672) | Northwestern University | 2006-08-01 |
| A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia (NCT00396565) | Janssen Pharmaceutical K.K. | 2006-07-01 |
| Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia (NCT00797277) | National Taiwan University Hospital | 2006-07-01 |
| A Definitive Estrogen Patch Study (ADEPT) (NCT00357006) | The Alfred | 2006-07-01 |
| Evaluation of the H1-coil Deep TMS in the Treatment of Negative Symptoms and Cognitive Deficit in Schizophrenia (NCT00445926) | Shalvata Mental Health Center | 2006-07-01 |
| Cognitive Therapy for Negative Symptoms and Functioning (NCT00350883) | University of Pennsylvania | 2006-07-01 |
| Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia. (NCT00380224) | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-07-01 |
| Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder. (NCT00325689) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2006-07-01 |
| An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. (NCT00391261) | Cambridge Health Alliance | 2006-07-01 |
| Escitalopram in Schizophrenia in OCD- Open Label Study (NCT00456937) | BeerYaakov Mental Health Center | 2006-07-01 |
| Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI) (NCT00453804) | State University of New York - Upstate Medical University | 2006-07-01 |
| Safety, PK and PD Study in Healthy Male Japanese Subjects (NCT00447941) | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-06-01 |
| A Study of the Dose Proportionality of Extended Release Paliperidone (NCT00791167) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-06-01 |
| A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia (NCT00686140) | Beijing HuiLongGuan Hospital | 2006-06-01 |
| Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes (NCT00338949) | Veterans Medical Research Foundation | 2006-06-01 |
| Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia (NCT00338832) | Veterans Medical Research Foundation | 2006-06-01 |
| Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia (NCT00265382) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2006-06-01 |
| First Episode Schizophrenia and Cannabis-Related Disorder Study (NCT00573287) | Dartmouth-Hitchcock Medical Center | 2006-06-01 |
| A Long-Term Study of JNS007ER in Patients With Schizophrenia (NCT01561898) | Janssen Pharmaceutical K.K. | 2006-06-01 |
| Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence (NCT01037075) | National Institute on Drug Abuse (NIDA) | 2006-05-14 |
| Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme (NCT00921362) | AstraZeneca | 2006-05-01 |
| Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet (NCT00324051) | Eli Lilly and Company | 2006-05-01 |
| The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory (NCT01494623) | Centre for Addiction and Mental Health | 2006-05-01 |
| Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (NCT00330863) | Northwell Health | 2006-05-01 |
| Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness (NCT00500695) | Rutgers, The State University of New Jersey | 2006-05-01 |
| Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine (NCT00315081) | University Hospital, Bonn | 2006-05-01 |
| Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II (NCT00377117) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2006-05-01 |
| Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia (NCT00337662) | Eli Lilly and Company | 2006-05-01 |
| Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal (NCT00314613) | Duke University | 2006-04-01 |
| A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode (NCT00378092) | Janssen Cilag N.V./S.A. | 2006-04-01 |
| A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia (NCT00316238) | Eli Lilly and Company | 2006-04-01 |
| Thinking Skills for Work in Severe Mental Illness (NCT01926613) | Dartmouth-Hitchcock Medical Center | 2006-04-01 |
| Smoking Relapse Prevention in Schizophrenia (NCT00320697) | North Suffolk Mental Health Association | 2006-04-01 |
| Oral Aripiprazole Open-Label Rollover Study (NCT01001702) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2006-04-01 |
| Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers (NCT00392236) | Northwell Health | 2006-04-01 |
| Effects of Antipsychotic Medications on Energy Intake and Expenditure (NCT00836251) | Washington University School of Medicine | 2006-04-01 |
| Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia (NCT00257192) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2006-04-01 |
| Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia (NCT00334126) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-04-01 |
| Optimizing Response in Psychosis Study (NCT00314327) | Northwell Health | 2006-04-01 |
| Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis (NCT00307216) | University of North Carolina, Chapel Hill | 2006-04-01 |
| Effectiveness of an Interactive Educational Website for Improving the Quality of Mental Health Care for People With Schizophrenia (NCT00312949) | Johns Hopkins Bloomberg School of Public Health | 2006-04-01 |
| Diabetes in Neuropsychiatric Disorders (NCT00446992) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2006-04-01 |
| Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia (NCT00320489) | Eli Lilly and Company | 2006-04-01 |
| Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia (NCT00231335) | Emory University | 2006-03-01 |
| Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? (NCT00306475) | Northwestern University | 2006-03-01 |
| The Effect of Cigarette Holders, Plastic Menthol Cigarettes, and Cognitive Behavioral Therapy for Smoking Reduction Among Schizophrenia Inpatients: A Comparative Study (NCT00302432) | Lev-Hasharon Mental Healtlh Center | 2006-03-01 |
| Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia (NCT00330551) | University of California, Los Angeles | 2006-03-01 |
| A Clinical Trial on the Antipsychotic Properties of Cannabidiol (NCT00309413) | University of Cologne | 2006-03-01 |
| Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia (NCT00409201) | Abarbanel Mental Health Center | 2006-03-01 |
| Trial of Cognitive Behavioral Therapy for Schizophrenia (NCT00300651) | Philipps University Marburg | 2006-03-01 |
| A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER (NCT00791713) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-03-01 |
| Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia (NCT00333177) | University of California, Los Angeles | 2006-03-01 |
| Family Motivational Intervention in Schizophrenia (NCT01167556) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2006-03-01 |
| Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis (NCT00369239) | Janssen Pharmaceutica N.V., Belgium | 2006-03-01 |
| Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) (NCT00303602) | Eli Lilly and Company | 2006-03-01 |
| Safety and Effectiveness of D-serine in Schizophrenia (NCT00322023) | Nathan Kline Institute for Psychiatric Research | 2006-03-01 |
| The Study of Atypical Antipsychotics-induced Metabolic Disturbances (NCT00937755) | Taipei Medical University Hospital | 2006-03-01 |
| Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia (NCT01036568) | National Institute on Drug Abuse (NIDA) | 2006-02-14 |
| Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder (NCT00316303) | Dartmouth-Hitchcock Medical Center | 2006-02-01 |
| Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients. (NCT00828958) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-02-01 |
| Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia (NCT01548612) | University of Sao Paulo | 2006-02-01 |
| Cognitive Determinants of Psychoeducation and Information in Psychoses (NCT00646256) | German Research Foundation | 2006-02-01 |
| A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia (NCT00455715) | Massachusetts General Hospital | 2006-02-01 |
| Transcranial Magnetic Stimulation for "Voices" (NCT00308997) | Yale University | 2006-02-01 |
| Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia (NCT00299702) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-02-01 |
| Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes (NCT00288353) | Northwestern University | 2006-01-01 |